Citations

Clear

959 citation(s) found for "Service, F J".

Frequency of Arrhythmias and Postural Orthostatic Tachycardia Syndrome in Patients With Marfan Syndrome: A Nationwide Inpatient Study
Wafa, Syed Emir Irfan , Chahal, C. Anwar A. , Sawatari, Hiroyuki , Khanji, Mohammed Y , Asatryan, Babken , Ahmed, Raheel , Deshpande, Saurabh , Providência, Rui , Deshmukh, Abhishek , Owens, Anjali , Padmanabhan, Deepak , Connolly, Heidi M. , Khan, Hassan , Asatryan, Babken , Ahmed, Raheel , Deshpande, Saurabh , Providencia, Rui , Deshmukh, Abhishek J , Owens, Anjali T , Somers, Virend K. , Padmanabhan, Deepak , Connolly, Heidi M , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Somers, Virend K.

Mayo Clinic

Journal of the American Heart Association | August 24, 2022 | Volume: 11 | Issue: 17 | Pages: No page available

10.1161/jaha.121.024939 | PMID 36000435 Get It

Background Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder affecting multiple systems, particularly the cardiovascular system. The leading causes of death in MFS are aortopathies and valvular disease. We wanted to identify the frequency of arrhythmia and postural orthostatic tachycardia syndrome, length of hospital stay, health care–associated costs (HAC), and in‐hospital mortality in patients with MFS. Methods and Results The National Inpatient Sample database from 2005 to 2014 was queried using International Classification of Diseases, Ninth Revision, Clinical Modification ( ICD‐9‐CM ) codes for MFS and arrhythmias. Patients were classified into subgroups: supraventricular tachycardia, ventricular tachycardia (VT), atrial fibrillation, atrial flutter, and without any type of arrhythmia. Data about length of stay, HAC, and in‐hospital mortality were also abstracted from National Inpatient Sample database. Adjusted HAC was calculated as multiplying HAC and cost‐to‐charge ratio; 12 079 MFS hospitalizations were identified; 1893 patients (15.7%) had an arrhythmia; and 4.9% of the patients had postural orthostatic tachycardia syndrome. Median values of length of stay and adjusted HAC in VT group were the highest among the groups (VT: 6 days, $18 975.8; supraventricular tachycardia: 4 days, $11 906.6; atrial flutter: 4 days, $11 274.5; atrial fibrillation: 5 days, $10431.4; without any type of arrhythmia: 4 days, $8336.6; both P =0.0001). VT group had highest in‐patient mortality (VT: 5.3%, atrial fibrillation: 4.1%, without any type of arrhythmia: 2.1%, atrial flutter: 1.7%, supraventricular tachycardia: 0%; P <0.0001) even after adjustment for potential confounders (without any type of arrhythmia versus VT; odds ratio [95% CI]: 3.18 [1.62–6.24], P =0.001). Conclusions Arrhythmias and postural orthostatic tachycardia syndrome in MFS were high and associated with increased length of stay, HAC, and in‐hospital mortality especially in patients with VT.
European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Aktaa, Suleman , Tzeis, Stylianos , Gale, Chris P , Ackerman, Michael J. , Arbelo, Elena , Behr, Elijah R. , Crotti, Lia , Chillou, Christian de , Deneke, Thomas , Friede, Tim , Leclercq, Christophe , Merino, José Luís , Semsarian, Chris, Verstrael, Axel , Zeppenfeld, Katja , Tfelt‐Hansen, Jacob , Crotti, Lia , Zeppenfeld, Katja , de Chillou, Christian , Deneke, Thomas , Figueiredo, Márcio , Friede, Tim , Leclercq, Christophe , Merino, Jose L , Semsarian, Christopher , Zeppenfeld, Katja , Tfelt-Hansen, Jacob , Reichlin, Tobias , Crotti, Lia , Behr, Elijah Raphael , Zeppenfeld, Katja , Arbelo, Elena , d'Avila, Andre

Mayo Clinic

Europace | August 24, 2022 | Volume: 25 | Issue: 1 | Pages: 199-210

10.1093/europace/euac114 | PMID 36753478 Get It

Abstract To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative. We followed the ESC methodology for QI development, which involves (i) the identification of the key domains of care for the management of patients with VA and the prevention of SCD by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. We identified eight domains of care for the management of patients with VA and the prevention of SCD: (i) structural framework, (ii) screening and diagnosis, (iii) risk stratification, (iv) patient education and lifestyle modification, (v) pharmacological treatment, (vi) device therapy, (vii) catheter ablation, and (viii) outcomes, which included 17 main and 4 secondary QIs across these domains. Following a standardized methodology, we developed 21 QIs for the management of patients with VA and the prevention of SCD. The implementation of these QIs will improve the care and outcomes of patients with VA and contribute to the prevention of SCD.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
Jatuworapruk, Kanon , Montgomery, Anna , Conway, Richard , Durcan, Laura, Graef, Elizabeth R. , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen , Cogo, Adriana Karina , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Malcata, Armando, Mateus, Elsa F , Schäfer, Martin , Scirè, Carlo Alberto , Sparks, Jeffrey A. , Strangfeld, Anja , Xavier, Ricardo Machado , Bhana, Suleman , Gore‐Massy, Monique , Hausmann, Jonathan S. , Sirotich, Emily , Sufka, Paul , Wallace, Zach, Machado, Pedro , Grainger, Rebecca , Ware, Anna , Gianfrancesco, Milena A , Conway, Richard , Durcan, Laura , Graef, Elizabeth R , Jayatilleke, Arundathi , Keen, Helen , Kilian, Adam , Young, Kristen J , Carmona, Loreto , Cogo, Adriana Karina , Duarte-García, Alí , Gossec, Laure , Hasseli, Rebecca , Hyrich, Kimme L , Langlois, Vincent , Lawson-Tovey, Saskia , Schaefer, Martin , Scirè, Carlo Alberto , Sigurdardottir, Valgerdur , Sparks, Jeffrey A , Xavier, Ricardo M , Bhana, Suleman , Hausmann, Jonathan S , Liew, Jean , Sirotich, Emily , Sufka, Paul , Wallace, Zachary S , Machado, Pedro M , Yazdany, Jinoos , Grainger, Rebecca , Robinson, Philip C , Strangfeld, Anja , Mateus, Elsa F , Carmona, Loreto , Duarte‐García, Alí , Lawson‐Tovey, Saskia , Liew, Jean W. , Yazdany, Jinoos , Robinson, Philip C.

Mayo Clinic

ACR Open Rheumatology | August 24, 2022 | Volume: 4 | Issue: 11 | Pages: 948-953

10.1002/acr2.11495 | PMID 36000538 Get It

ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy
Hopfner, Franziska , Tietz, Anja, Ruf, Viktoria , Ross, Owen A. , Koga, Shunsuke , Attems, Johannes , Beach, Thomas, Beller, Allison , Duyckaerts, Charles, Evsyukov, Valentin, Flanagan, Margaret E. , Frosch, Matthew P. , Gearing, Marla , Gelpí, Ellen , Gerpen, Jay A. van, Glass, Jonathan D. , Grinberg, Lea T. , Halliday, Glenda M. , Höllerhage, Matthias , Huitinga, Inge , Keene, Dirk, Kovács, Gábor G. , Lee, Edward B. , Xiong, Chengjie , Martı́, Marı́a José , Mackenzie, Ian R. , Mollenhauer, Brit , Neumann, Manuela , Newell, Kathy L. , Pendziwiat, Manuela , Molina‐Porcel, Laura , Rábano, Alberto , Rajput, Alex, Rajput, Ali H. , Reimann, Regina , Selvackadunco, Sashika , Simuni, Tanya , Svenningsson, Per , Trenkwalder, Claudia , Troakes, Claire , Trojanowski, John Q. , Uitti, Ryan J. , Xie, Tao , Ximelis, Teresa , Yebenes, Justo, Müller, Ulrich , Schellenberg, Gerard D., Herms, Jochen , Kuhlenbäumer, Gregor , Deuschl, Günther , Gelpi, Ellen , Van Gerpen, Jay A, Halliday, Glenda , Irwin, David J , Mollenhauer, Brit , Pantelyat, Alex , Svenningsson, Per , Höglinger, Günter U , Koga, Shunsuke , Ross, Owen A , Kovacs, Gabor G , Xiong, Chengjie , Grinberg, Lea , Molina-Porcel, Laura , Troakes, Claire , Hopfner, Franziska , Lee, Edward B , Simuni, Tanya , Dickson, Dennis W. , Aguzzi, Adriano , Cheshire, William P. , Deerlin, Vivianna M. Van , Desplats, Paula , Deuschl, Günther , Duyckaerts, Charles , Ellinghaus, David , Franke, André , Ghetti, Bernardino , Helbig, Ingo , Irwin, David J. , McKeith, Ian G. , McLean, Catriona , Pantelyat, Alexander , Peters, Annette , Matěj, Radoslav , Scott, William K. , Seeley, William W. , Stadelmann, Christine , Thomas, Alan , White, Charles L. , Wszołek, Zbigniew K. , Schellenberg, Gerard D., Höglinger, Günter U. , Flanagan, Margaret E

Mayo Clinic

Movement Disorders | August 23, 2022 | Volume: 37 | Issue: 10 | Pages: 2110-2121

10.1002/mds.29164 | PMID 35997131 Get It

ABSTRACT Background Multiple System Atrophy is a rare neurodegenerative disease with alpha‐synuclein aggregation in glial cytoplasmic inclusions and either predominant olivopontocerebellar atrophy or striatonigral degeneration, leading to dysautonomia, parkinsonism, and cerebellar ataxia. One prior genome‐wide association study in mainly clinically diagnosed patients with Multiple System Atrophy failed to identify genetic variants predisposing for the disease. Objective Since the clinical diagnosis of Multiple System Atrophy yields a high rate of misdiagnosis when compared to the neuropathological gold standard, we studied only autopsy‐confirmed cases. Methods We studied common genetic variations in Multiple System Atrophy cases (N = 731) and controls (N = 2898). Results The most strongly disease‐associated markers were rs16859966 on chromosome 3, rs7013955 on chromosome 8, and rs116607983 on chromosome 4 with P ‐values below 5 × 10 −6 , all of which were supported by at least one additional genotyped and several imputed single nucleotide polymorphisms. The genes closest to the chromosome 3 locus are ZIC1 and ZIC4 encoding the zinc finger proteins of cerebellum 1 and 4 (ZIC1 and ZIC4). Interpretation Since mutations of ZIC1 and ZIC4 and paraneoplastic autoantibodies directed against ZIC4 are associated with severe cerebellar dysfunction, we conducted immunohistochemical analyses in brain tissue of the frontal cortex and the cerebellum from 24 Multiple System Atrophy patients. Strong immunohistochemical expression of ZIC4 was detected in a subset of neurons of the dentate nucleus in all healthy controls and in patients with striatonigral degeneration, whereas ZIC4‐immunoreactive neurons were significantly reduced inpatients with olivopontocerebellar atrophy. These findings point to a potential ZIC4‐mediated vulnerability of neurons in Multiple System Atrophy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Clinical applications of heart rhythm monitoring tools in symptomatic patients and for screening in high-risk groups
Carrington, M , Chahal, C. Anwar A. , Epstein, Andrew E. , Gallina, Sabina , Fedorowski, Artur , Sutton, Richard , Khanji, Mohammed Y , Carrington, Mafalda , Fedorowski, Artur , Sutton, Richard , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Providência, Rui , Ricci, Fabrizio

Mayo Clinic

EP Europace | August 19, 2022 | Volume: 24 | Issue: 11 | Pages: 1721-1729

10.1093/europace/euac088 | PMID 35983729 Get It

Abstract Recent technological advances have facilitated and diversified the options available for the diagnosis of cardiac arrhythmias. Ranging from simple resting or exercise electrocardiograms to more sophisticated and expensive smartphones and implantable cardiac monitors. These tests and devices may be used for varying periods of time depending on symptom frequency. The choice of the most appropriate heart rhythm test should be guided by clinical evaluation and optimized following accurate characterization of underlying symptoms, ‘red flags’, risk factors, and consideration of cost-effectiveness of the different tests. This review provides evidence-based guidance for assessing suspected arrhythmia in patients who present with symptoms or in the context of screening, such as atrial fibrillation or advanced conduction disturbances following transcatheter aortic valve implantation in high-risk groups. This is intended to help clinicians choose the most appropriate diagnostic tool to facilitate the management of patients with suspected arrhythmias.
Heterozygous NOTCH1 Variants Cause CNS Immune Activation and Microangiopathy
Helman, Guy , Zarekiani, Parand , Tromp, Samantha A. M., Andrews, Ashley , Bonkowsky, Joshua L. , Chassevent, Anna , Giorgio, Elisa , Pippucci, Tommaso , Wei, Shen, Smith‐Hicks, Constance , Vaula, Giovanna , Schimmel, Mareike , Vollert, Kurt, Shimizu, Fumitaka , Kanda, Takashi , Lynch, Matthew , Roscioli, Tony , Taft, Ryan J. , Simons, Cas , Bugiani, Marianna , Shen, Wei , Bonkowsky, Joshua L , Willemsen, Michèl A A P , Shimizu, Fumitaka , van der Knaap, Marjo S , Shen, Wei , Giorgio, Elisa , Simons, Cas , Botto, Lorenzo D. , Kuijpers, Taco Willem , Knaap, Marjo S. van der

Mayo Clinic

Annals of Neurology | August 10, 2022 | Volume: 92 | Issue: 5 | Pages: 895-901

10.1002/ana.26477 | PMID 35947102 Get It

NOTCH1 belongs to the NOTCH family of proteins that regulate cell fate and inflammatory responses. Somatic and germline NOTCH1 variants have been implicated in cancer, Adams‐Oliver syndrome, and cardiovascular defects. We describe 7 unrelated patients grouped by the presence of leukoencephalopathy with calcifications and heterozygous de novo gain‐of‐function variants in NOTCH1. Immunologic profiling showed upregulated CSF IP‐10, a cytokine secreted downstream of NOTCH1 signaling. Autopsy revealed extensive leukoencephalopathy and microangiopathy with vascular calcifications. This evidence implicates that heterozygous gain‐of‐function variants in NOTCH1 lead to a chronic central nervous system (CNS) inflammatory response resulting in a calcifying microangiopathy with leukoencephalopathy. ANN NEUROL 2022;92:895–901
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
Bewicke‐Copley, Findlay , Korfi, Koorosh , Araf, Shamzah, Hodkinson, Brendan P. , Kumar, Emil , Cummin, Thomas , Ashton‐Key, Margaret , Barrans, Sharon, Hoppe, Suzan van, Burton, Cathy , Elshiekh, Mohamed , Rule, Simon , Crosbie, Nicola, Clear, Andrew , Calaminici, Maria , Runge, Hendrik F.P. , Hills, Robert K. , Sha, Chulin , Painter, Daniel , Smith, Alexandra , Naresh, Kikkeri N. , Westhead, David R. , Steele, Andrew J. , Hodson, Daniel J. , Balasubramanian, Sriram , Runge, Hendrik , Scott, David W , Nagano, Ai , Davies, Andrew , Painter, Daniel , Smith, Alexandra , Gribben, John G. , Westhead, David R , Okosun, Jessica , Steele, Andrew , Hodson, Daniel J , Johnson, Peter , Wang, Jun , Fitzgibbon, Jude , Naresh, Kikkeri N , Scott, David W. , Rimsza, Lisa M. , Menon, Geetha, Davies, John R., Davies, Andrew , Johnson, Peter , Fitzgibbon, Jude

Mayo Clinic

Blood Advances | August 10, 2022 | Volume: 7 | Issue: 5 | Pages: 845-855

10.1182/bloodadvances.2022007536 | PMID 35947123 Get It

Abstract Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic signature. In our study, we have focused attention on the changes in GEP accompanying DLBCL relapse using archival paired diagnostic/relapse specimens from 38 de novo patients with DLBCL. COO remained stable from diagnosis to relapse in 80% of patients, with only a single patient showing COO switching from activated B-cell–like (ABC) to germinal center B-cell–like (GCB). Analysis of the transcriptomic changes that occur following relapse suggest ABC and GCB relapses are mediated via different mechanisms. We developed a 30-gene discriminator for ABC–DLBCLs derived from relapse-associated genes that defined clinically distinct high- and low-risk subgroups in ABC–DLBCLs at diagnosis in datasets comprising both population-based and clinical trial cohorts. This signature also identified a population of &lt;60-year–old patients with superior PFS and OS treated with ibrutinib–R-CHOP as part of the PHOENIX trial. Altogether this new signature adds to the existing toolkit of putative genetic predictors now available in DLBCL that can be readily assessed as part of prospective clinical trials.
Beyond service education: Impacting the human experience with sustained training utilizing the Experience Model of Communication
Packard, Jennifer S., Brustad, Rebecca A., Hoplin, Jane M., Stevens, Sheila K., Packard, Jennifer S., Brustad, Rebecca

Mayo Clinic

Patient Experience Journal | August 4, 2022 | Volume: 9 | Issue: 2 | Pages: 87-93

10.35680/2372-0247.1691 Get It

Patients scheduling or checking in for medical appointments often share with frontline employees’ details of their stories, including their worries, prior negative experiences, and hopes. These interactions require employees to not only complete their task, but also to be mindfully present, picking up on important social cues and showing appropriate emotional congruence and empathic understanding. Based on a review of recorded patient calls, a gap was identified in the communication skills of desk and scheduling staff at this large academic medical center, and a sustained training program was created to fill this gap. The training is centered on an evolving set of theoretical principles and skills that have come to be known as the Experience Model of Communication (XMOC). We wanted to understand if training in XMOC, a set of skills essential for healthcare providers, would also be beneficial for frontline staff. The training was evaluated with pre/post surveys, listening sessions, an annual evaluation, and quarterly tracking of patient experience scores, and findings suggest that the training content has had a positive impact. We continue to build and evaluate the training program to identify and refine the elements that make up XMOC and the most effective ways to transfer that learning to the staff who benefit. Experience Framework This article is associated with the Staff & Provider Engagement lens of The Beryl Institute Experience Framework (https://www.theberylinstitute.org/ExperienceFramework). Access other PXJ articles related to this lens. Access other resources related to this lens.
Genomic and phenomic landscape of clonal hematopoiesis in over a million ancestrally diverse participants
Uddin, Md Mesbah , Weinstock, Joshua S. , Niroula, Abhishek , Vlasschaert, Caitlyn , Koyama, Satoshi , Nakao, Tetsushi , Urbut, Sarah , Paruchuri, Kaavya , Silver, Alexander J. , Mack, Taralynn , Wong, Megan , Bhattacharya, Romit , Jorshery, Saman Doroodgar , Raddatz, Michael A. , Hornsby, Whitney , Kresge, Hailey A. , Cho, Kelly , Sun, Yan V. , Pyarajan, Saiju , Chen, Yii‐Der Ida , Sheu, Wayne H-H , Hung, Yi‐Jen , Hidalgo, Bertha , Fornage, Myriam , Kaplan, Robert C., Williams, L. Keoki , Province, Mike , Kardia, Sharon, Peyser, Patricia A., Yanek, Lisa R. , Becker, Lewis C. , Meyers, Deborah A. , Naseri, Take, Barnes, Kathleen C. , Redline, S S, Schwartz, D A, Shoemaker, M. Benjamin , Palmer, Nicholette D., Bowden, Donald W., Kumar, Rajesh, Nj, Smith, Floyd, James, Tracy, Russell, Bis, Joshua C. , SS, Rich, Boerwinkle, Eric, Wang, Zhe, Silverman, Edwin K. , Auer, Paul L. , Reiner, Alexander P. , Ebert, Benjamin L. , Natarajan, Pradeep , Uddin, Md M , Niroula, Abhishek , Weinstock, Joshua S , Bhattacharya, Romit , Ebert, Benjamin L , Natarajan, Pradeep , Yu, Zhi , Zekavat, Seyedeh M , Truong, Buu Minh Thanh , Haidermota, Sara , Honigberg, Michael C. , Zhang, Martin Jinye , Dron, Jacqueline S. , Heimlich, Jonathan Brett , Sankaran, Vijay G. , Griffin, Gabriel K. , Gibson, Christopher James , Wilson, Peter W.F. , Genovese, Giulio , Xu, Yaomin , Savona, Michael R. , Raffield, Laura M. , Arnett, Donna K. , Konkle, Barbara A. , Peyser, Patricia A. , Smith, Jennifer A. , Mathias, Rasika A. , Andrade, Mariza de , Darbar, Dawood , He, Jiang , Blangero, John , Weiss, Scott T. , Custer, Brian , Minster, Ryan L , Viali, Satupaitea , Mitchell, Braxton D. , Palmer, Nicholette D , Freedman, Barry I. , Bowden, Donald W. , Albert, Christine M. , Smith, Nicholas, Tracy, Russell P. , Psaty, Bruce M. , Taylor, Kent D. , Rotter, Jerome I. , Boerwinkle, Eric , Vasan, Ramachandran S. , Lubitz, Steven A. , Ellinor, Patrick T. , Loos, Ruth J. F. , Yun, Jeong H. , Cho, Michael H. , Abecasis, Gonçalo R. , Kooperberg, Charles , Reiner, Alex P. , Jaiswal, Siddhartha , Bick, Alexander G.

Mayo Clinic

No container title available | July 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2022.07.29.22278015 Get It

Abstract With aging, somatic mutations in hematopoietic stem and progenitor cells (HSPC) can give rise to clonal hematopoiesis of indeterminate potential (CHIP), a premalignant state associated with diverse age-related diseases. Here we report the largest multi-ancestry genome-wide analysis of CHIP to date (N = 1,018,305), including individuals of African (N = 85,978), Admixed American (N = 191,371), East Asian (N = 13,532), European (N = 694,015), and South Asian (N = 13,193) ancestry. Multi-ancestry meta-analyses identified 72 genome-wide significant loci, including 44 novel associations implicating genes such as AFF1 , ATF7IP , ATP8B4 , BCL2 , CEBPA , CYRIA , DNM2 , ELF1 , NKX2-3 , PIK3CB , PRDM16 , RPN1 , TERC , and TRIM4 . Notably, variants at MECOM and PHF20L1 showed opposite allelic effects between DNMT3A - and non- DNMT3A -driven CHIP, highlighting driver-specific germline influences. Implicated loci converge on pathways regulating telomere maintenance, cell-cycle control, hematopoietic transcription, DNA damage response and immune signaling. These findings support a model in which germline variation both expands the HSPC pool and biases clonal selection in a driver-dependent manner, providing a mechanistic basis for inter-individual heterogeneity in CHIP. Phenome-wide association analyses further linked CHIP to hematologic, neoplastic, and circulatory traits, with enrichment across hematopoietic and non-hematopoietic cell types. Together, this work expands the genomic and phenomic landscape of CHIP and reveals germline–somatic interactions that shape clonal evolution during aging.